You are here
News Release
Thursday, June 2, 2022
Immune modulator drugs improved survival for people hospitalized with COVID-19
A large randomized, placebo-controlled clinical trial led by the 2023 蜜芽传媒 shows that treating adults hospitalized with COVID-19 with infliximab or abatacept 鈥 drugs widely used to treat certain autoimmune diseases 鈥 did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.
Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. As part of the聽Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)聽public-private initiative, NIH launched the to determine if certain drugs that help minimize the effects of an overactive immune response could speed recovery and reduce deaths in adults hospitalized with moderate to severe COVID-19. The ACTIV-1 master protocol included three sub-studies; each one tested an immune modulator drug as compared to a placebo. This approach allowed for coordinated and efficient evaluation of multiple investigational agents simultaneously.
NIH鈥檚 National Center for Advancing Translational Sciences (NCATS) coordinated and oversaw the trial with funding from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.
鈥淭hese promising ACTIV-1 results demonstrate the collaborative power of public-private partnerships to accelerate therapeutic answers during this unprecedented global health crisis,鈥 said Acting 蜜芽传媒 Lawrence A. Tabak, D.D.S., Ph.D. 鈥淲orking together, NIH and our ACTIV partners have brought to bear the best tools and clinical trial designs in our research arsenals. The innovative ACTIV model is bringing greater clarity to the search for effective, evidence-based COVID-19 treatments.鈥
ACTIV-1 participants were randomly assigned to one of the immune modulator drugs or placebo in addition to the standard of care, which may include remdesivir (Veklury) supplied by Gilead Sciences, Inc. About 90% received remdesivir, and about 85% received dexamethasone.
Investigators monitored participants and recorded their clinical status daily while hospitalized according to an eight-point scale ranging from not hospitalized with no limitations on activities to death. The full report on these data in a peer-reviewed scientific journal is expected in fall of 2022, and a preprint will be available sooner.
The topline results showed:
- Compared to placebo, participants receiving infliximab (Remicade) displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of discharge from hospital. Substantial improvements for both key secondary endpoints of mortality and clinical status at 28 days were observed. The 518 participants receiving infliximab had a death rate of 10.0%, compared to 14.5% for the 519 participants receiving placebo, resulting in 40.5% lower adjusted odds of dying. The relative improvement in mortality was similar in both moderately and severely ill participants. People in the infliximab group had 43.8% better odds of clinical improvement than those in the placebo group. Infliximab, which was given as a single dose, was developed and is marketed by Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
- Compared to placebo, participants receiving abatacept (Orencia) displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of discharge from hospital. Substantial improvements for both key secondary endpoints of mortality and clinical status at 28 days were observed. The 509 participants receiving abatacept had a death rate of 11.0%, compared to 15.0% for the 513 participants receiving placebo, resulting in 37.4% lower adjusted odds of dying. The relative improvement in mortality was similar in both moderately and severely ill participants. People in the abatacept group had 34.2% better odds of clinical improvement than those in the placebo group. Abatacept, which was given as a single dose, was developed and is marketed by Bristol Myers Squibb.
- Enrollment into the third sub-study evaluating the investigational medicine cenicriviroc was stopped in September 2021 after an independent data and safety monitoring board (DSMB) recommended closing it due to lack of efficacy. Cenicriviroc was provided by AbbVie.
The results will be made available to treatment guideline groups and regulatory bodies.
鈥淲hen given in addition to standard of care treatments, like remdesivir and dexamethasone, infliximab and abatacept each offered a substantial reduction in mortality,鈥 said the trial鈥檚 protocol chair, William G. Powderly, M.D., director of the Institute for Clinical and Translational Sciences and co-director of the Division of Infectious Diseases at Washington University School of Medicine in St. Louis. 鈥淭hese drugs could potentially add to the therapeutic options available for the treatment of patients hospitalized with COVID-19.鈥
From October 2020 through December 2021, the ACTIV-1 Immune Modulators clinical trial enrolled 1,971 participants at 46 medical facilities in the United States and 23 medical facilities in Latin America. The study was reviewed periodically by an independent DSMB, and no safety concerns were noted during the conduct of the trial. 聽聽聽
NCATS鈥 Clinical and Translational Science Awards (CTSA) Program and the Trial Innovation Network played a key role in enrolling participants in the United States.
鈥淢ore than half of the CTSA Program sites contributed their infrastructure and expertise to speed completion of this trial,鈥 said Joni L. Rutter, Ph.D., acting director of NCATS. 鈥淭his collaborative and efficient multinational platform trial design streamlined our ability to urgently and robustly test promising therapies for treating people hospitalized with COVID-19.鈥
For more information about the trial, please visit clinicaltrials.gov and search identifier .
About HHS, ASPR, and BARDA:聽HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures 鈥 vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, BARDA-supported products have achieved 62 FDA approvals, licensures or clearances. For more on BARDA鈥檚 development portfolios and on partnering with BARDA, visit聽.
About the National Center for Advancing Translational Sciences (NCATS):聽NCATS conducts and supports research on the science and operation of translation 鈥 the process by which interventions to improve health are developed and implemented 鈥 to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit .
About the 2023 蜜芽传媒 (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health庐